Heart failure with reduced ejection fraction
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
... Introduction Besides the risk for mortality and recurrent hospitalizations, patients with heart failure with reduced ejection fraction HFrEF also suffer from impaired health status.1,2 I[r] ...
11
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
... Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three r[r] ...
25
Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction.
... be reduced, and that structural and functional remodeling would occur with BAT ( 27–29 ...Patients With Chronic Heart Failure) trial, morbidity and mortality were reduced when ...
14
Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
... different heart failure medications on SBP, patients in RALES and EMPHASIS-HF with the lowest baseline SBP experienced an increase in SBP after randomi- zation in both treatment groups, although the ...
12
Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
... patients with higher doses of loop diuretics showed signs of more severe heart fail- ure and ...the heart failure guidelines could facilitate a better uptitration of ...
13
Circulating neuregulin1-beta in heart failure with preserved and reduced left ventricular ejection fraction
... was reduced in both HFpEF and, even more, in HFrEF compared with healthy ...ated with worse ...protective with higher concentrations tending to be as- sociated with better ...1-β ...
12
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
... treatment with SGLT2 ...correlated with changes in NT-proBNP or with changes in hematocrit in individual patients treated with empagliflozin, both after 4 weeks and after 52 ...
13
Serial heart rate measurement and mortality after acute heart failure.
... presenting with acute HF at CHU of Liège, Belgium, between January 2010 and December ...patients with ≥1 following criteria were further disqualified respiratory support, cardiogenic shock, acute coronary ...
4
Prognostic Value of Dynamic Changes in Pulmonary Congestion During Exercise Stress Echocardiography in Heart Failure With Preserved Ejection Fraction
... patients with acute heart failure: ...Patients With Heart ...Patients With Heart Failure With Reduced or Preserved Ejection Fraction and ...
30
Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach
... patients with HFpEF are at risk of PH because of elevated left pressure transmitted back to the pulmonary circulation, resulting in pulmonary venous ...vasculature, with muscularization of the pulmonary ...
20
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial
... level >5.2 mmol/L at screening (or >5.4 mmol/L at randomisation) was an exclusion criterion, which might have led to the selection of patients less prone to develop hyperkalaemia and the proto- col included ...
10
A personalized algorithm-based discharge checklist in patients with acute heart failure
... patients with heart failure with preserved ejection fraction ...patients with heart failure, including older patients with HFpEF ...deficiency ...
29
Tumour biomarkers: association with heart failure outcomes.
... There are limitations to the current study. First of all, the presence of cancer at baseline was not consistently studied (e.g. by imaging studies), and follow-up was mainly aimed to describe CV events and mortality, ...
13
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
... 4. Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. ...
35
Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score
... and reduced diastolic compliance, rather than reduced LV contractility, appear important for diagnosis and for prediction of cardiac ...associated with outcome have been reported, the set of ...
14
Prognostic impact of plasma volume estimated from hemoglobin and hematocrit in heart failure with preserved ejection fraction
... patients with decompensated HF exhibit a 40% increase in PV compared with healthy controls 9 ...associated with clinical outcomes in patients with acute HF and HF with reduced ...
28
The continuous heart failure spectrum: moving beyond an ejection fraction classification
... used heart failure (HF) patients with low left ventricular ejection fraction (LVEF) to select study pop- ulations with high risk to enhance statistical ...(HF with ...
12
Direct Thrombin Inhibitors Prevent Left Atrial Remodeling Associated With Heart Failure in Rats
... rats with MI compared with sham animals and only ...rats with MI ( Figure 1A ). Remarkably, treatment with the vitamin K antagonist, warfarin, did not significantly reduce left atrial ...
13
Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction
... of heart failure with preserved ejection fraction The four descriptive models of HFpEF were used for which the FC-HF was required for all (Figure ...structural heart disease ...
11
View of Support Therapy for Advanced Heart Failure
... Définition de l ’insuffisance cardiaque avancée L ’ICA correspond au stade D de la classification ACCF/ AHA [3] (American College of Cardiology Foundation & American Heart Association) décrit comme le stade où ...
13